Webster Brian Daniel 4

What Happened

• Brian Daniel Webster, President and Chief Executive Officer of Kestra Medical Technologies, sold a total of 15,000 common shares in three open‑market transactions on February 17, 2026, generating approximately $384,020 in proceeds. The trades were reported as: 11,635 shares at $25.39 ($295,456), 3,272 shares at $26.29 ($86,036), and 93 shares at $27.18 ($2,528). These were sales (S), not purchases.

Key Details

• Transaction date: February 17, 2026; Form 4 filed February 19, 2026 (timely within the usual two‑business‑day window).
• Total shares sold: 15,000; total proceeds: ~$384,020.
• Reported per‑share figures shown as weighted averages: first block $25.39 (actual prices ranged $25.0150–$26.0100), second $26.29 (ranged $26.0200–$26.9998), third $27.18 (ranged $27.0771–$27.1800).
• Footnote: Transactions occurred pursuant to a Rule 10b5‑1 trading plan adopted September 29, 2025.
• Shares owned after the transaction: not specified in the excerpts provided.

Context

• Sales under a 10b5‑1 plan are pre‑arranged and often reflect scheduled dispositions rather than ad hoc sales based on current company developments; they are typically considered routine rather than a direct signal of the insider’s current view of the company.
• For retail investors, purchases tend to be more informative about insider conviction; this filing documents routine sell transactions by the CEO under a pre‑set plan.